Home LiteratureArticle Details
PMID: 9583686 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Type I interferon induction of the Cdk-inhibitor p21WAF1 is accompanied by ordered G1 arrest, differentiation and apoptosis of the Daudi B-cell line.

Oncogene ·Vol. 16 ·No. 14 ·1998-04-09 ·Pages 1885-90

Subramaniam PS, Cruz PE, Hobeika AC, Johnson HM

Abstract

We show, in this study, that type I IFN induction of the cyclin-dependent kinase (cdk) inhibitor p21WAF1 in the human Burkitt lymphoma B cell-line Daudi and ensuing cell cycle arrest correlate with the terminal differentiation of these cells, and is ultimately followed by apoptosis and cell death. The expression of p21WAF1 paralleled the onset of G1 arrest and the reduction of surface IgM expression which was used as a marker of the differentiation response, and the IFN treated cells acquired a typical plasma cell-like morphology. The type II IFN IFNgamma, which does not inhibit the growth of Daudi cells, did not induce the expression of p21WAF1, nor affect the expression of surface IgM. The induction of p21WAF1 which paralleled the inhibition of the phosphorylation of the retinoblastoma protein, pRB, was preceded by the strong reduction in c-myc levels. We propose that the coupled down-regulation of c-myc and induction of p21WAF1 may be crucial to the induction of differentiation and G1 arrest in Daudi cells by type I IFN. Growth arrest and differentiation was followed by apoptosis and cell death, and was accompanied by the induction of the activity of the apoptotic ICE-family protease CPP32. G1 arrest and differentiation followed by apoptotic cell death are characteristics of terminal differentiation. Thus, our data suggest that the induction of p21WAF1 and G1 arrest mediated by type I IFN in Daudi cells is part of terminal differentiation response in these cells, highlighting a role for type I IFN as B cell terminal differentiation factors.

MeSH Terms
Apoptosis/drug effects,genetics B-Lymphocytes/drug effects,enzymology,pathology Burkitt Lymphoma Cell Differentiation/drug effects,genetics Cyclin-Dependent Kinase Inhibitor p21 Cyclin-Dependent Kinases/antagonists & inhibitors Cyclins/biosynthesis,physiology G1 Phase/drug effects,genetics Humans Interferon Type I/pharmacology Tumor Cells, Cultured
Chemicals
CDKN1A protein, human Cyclin-Dependent Kinase Inhibitor p21 Cyclins Interferon Type I Cyclin-Dependent Kinases
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Subramaniam P S
Department of Microbiology and Cell Science, University of Florida, Gainesville 32611, USA.
Cruz P E
Hobeika A C
Johnson H M
Article Info
Journal
Oncogene
Abbr.
Oncogene
ISSN
0950-9232
Published
1998-04-09
Pages
1885-90
Language
English
Region
England
NLM ID
8711562
Subset
IM
Grants
NCI NIH HHS · CA 38587 · United States
NCI NIH HHS · CA 69959 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com